Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma
- PMID: 22175904
- DOI: 10.1111/j.1365-2559.2011.04060.x
Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma
Abstract
Aims: It has recently been shown that podoplanin, a mucin-type glycoprotein, is expressed by cancer cells and cancer-associated fibroblasts (CAFs), and promotes cancer cell migration and invasiveness. The biological role of podoplanin expression in tumour stroma of invasive ductal carcinoma of the breast (IDC) has not been determined.
Methods and results: Podoplanin expression was analysed in 117 cases of IDC and 27 cases of fibrocystic change, as well as in breast cancer cell lines, with the use of immunohistochemistry and real-time polymerase chain reaction. In 82.1% of analysed tumours, podoplanin was found only in CAFs. Only two of 117 IDC cases (1.7%) were characterized by expression of this glycoprotein in cancer cells. None of the fibrocystic changes or stroma surrounding normal ducts showed podoplanin expression. Podoplanin-positive CAFs correlated with tumour size (P = 0.0125), grade of malignancy (P = 0.0058), lymph node metastasis (P = 0.0149), lymphovascular invasion (LVI) (P = 0.0486) and Ki67 expression in cancer cells (P = 0.0128). High-level podoplanin expression (>50% of positive stroma) in the tumour stroma was significantly associated with a negative oestrogen status (P = 0.0201). Univariate, but not multivariate, analysis showed that podoplanin expression by CAFs was associated with poor patient outcome (P = 0.0202).
Conclusions: Our results suggest that podoplanin expression by CAFs could be an unfavourable prognostic marker for IDC.
© 2011 Blackwell Publishing Limited.
Similar articles
-
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer.Breast Cancer Res Treat. 2012 Jul;134(1):237-44. doi: 10.1007/s10549-012-1984-x. Epub 2012 Feb 17. Breast Cancer Res Treat. 2012. PMID: 22350732
-
Impact of different tumour stroma assessment methods regarding podoplanin expression on clinical outcome in patients with invasive ductal breast carcinoma.Anticancer Res. 2013 Apr;33(4):1447-55. Anticancer Res. 2013. PMID: 23564785
-
Podoplanin expression in cancer-associated fibroblasts correlates with VEGF-C expression in cancer cells of invasive ductal breast carcinoma.Neoplasma. 2013;60(5):516-24. doi: 10.4149/neo_2013_067. Neoplasma. 2013. PMID: 23790170
-
Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series.Biosci Rep. 2013 Dec 12;33(6):e00085. doi: 10.1042/BSR20130060. Biosci Rep. 2013. PMID: 24229053 Free PMC article. Review.
-
Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review.Int J Oncol. 2013 Jun;42(6):1849-57. doi: 10.3892/ijo.2013.1887. Epub 2013 Apr 8. Int J Oncol. 2013. PMID: 23588876 Review.
Cited by
-
Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.Monoclon Antib Immunodiagn Immunother. 2015 Feb;34(1):44-50. doi: 10.1089/mab.2014.0087. Monoclon Antib Immunodiagn Immunother. 2015. PMID: 25723283 Free PMC article.
-
Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth.Oncotarget. 2015 Apr 20;6(11):9531-41. doi: 10.18632/oncotarget.3371. Oncotarget. 2015. PMID: 25909164 Free PMC article.
-
Podoplanin - a small glycoprotein with many faces.Am J Cancer Res. 2016 Jan 15;6(2):370-86. eCollection 2016. Am J Cancer Res. 2016. PMID: 27186410 Free PMC article. Review.
-
The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective.J Oncol. 2019 Nov 22;2019:6240505. doi: 10.1155/2019/6240505. eCollection 2019. J Oncol. 2019. PMID: 31885581 Free PMC article. Review.
-
Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung.J Cancer Res Clin Oncol. 2013 Nov;139(11):1869-78. doi: 10.1007/s00432-013-1502-5. Epub 2013 Sep 7. J Cancer Res Clin Oncol. 2013. PMID: 24013219
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical